Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
Business Of Biotech
00:00
The Advantages of Accelerated Status With FDA and EMA
The company obtained orphan drug status. ODD, especially in Europe is very advantageous because you do not pay for anything. For example, if you are a ODD, you have an expansion of your exclusivity to your right on the data. So I think having ODD and especially fast like designation and everything, that puts you in the priority to have really two meetings with the FDA.
Transcript
Play full episode
